| AASLD

<div>Background: Macroautophagy (referred to as autophagy hereafter) is a major intracellular lysosomal degradation pathway that is responsible for the degradation of misfolded/damaged proteins and organelles. Previous studies showed that autophagy protects against acetaminophen (APAP)-induced injury (AILI) via selective removal of damaged mitochondria and APAP protein adducts.

INTESTINAL EPITHELIAL CELL OSTEOPONTIN PROTECTS FROM MASH BY CHANGING THE COMPOSITION OF THE GUT MICROBIOME AND BILE ACIDS

Read more about INTESTINAL EPITHELIAL CELL OSTEOPONTIN PROTECTS FROM MASH BY CHANGING THE COMPOSITION OF THE GUT MICROBIOME AND BILE ACIDS

<div>Background: osteopontin (OPN, encoded by SPP1) is involved in chronic liver disease. Previous studies reported that intestinal OPN regulates the gut microbiota, however the role of intestinal epithelial cell (IEC)-derived OPN in metabolic dysfunction-associated steatohepatitis (MASH) is unknown.

HEPATOCYTE-SPECIFIC HIF-1α DELETION ACCELERATES NON-ALCOHOLIC STEATOHEPATITIS PROGRESSION TO LIVER FIBROSIS

Read more about HEPATOCYTE-SPECIFIC HIF-1α DELETION ACCELERATES NON-ALCOHOLIC STEATOHEPATITIS PROGRESSION TO LIVER FIBROSIS

<div>Background: Non-alcoholic steatohepatitis (NASH) is prevalent, yet lacks for effective treatments to hinder rapid fibrosis progression, which is the main factor that limits patient prognosis. The role of Hypoxia-inducible factor 1α (HIF-1α) in NASH progression remains unclear. This study investigates the impact and mechanism of hepatocyte-specific HIF-1α deletion on NASH fibrosis, aiming to uncover a novel therapeutic target.

MOLECULAR SIGNATURE OF PERIPHERAL CIRCULATING TUMOR CELLS IN CANCER PROGRESSION OF HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY ATEZOLIZUMAB PLUS BEVACIZUMAB

Read more about MOLECULAR SIGNATURE OF PERIPHERAL CIRCULATING TUMOR CELLS IN CANCER PROGRESSION OF HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY ATEZOLIZUMAB PLUS BEVACIZUMAB

<div>Background: The mechanisms leading to cancer progression of hepatocellular carcinoma (HCC) such as acquired resistance to immunotherapies and metastatic progression are not clear. Circulating tumor cells (CTCs) have been defined as cancer cells released into the blood circulation from primary tumor. CTCs have notable advantages in that they are noninvasive and real-time biomarker that provide information about metastatic process.

ESTABLISHMENT OF PFIC 3 MOUSE MODEL CARRYING HUMAN-LIKE BILE ACID COMPOSITION BY IN VIVO LIVER-SPECIFIC GENE DELETION USING ADENO-ASSOCIATED VIRUS AND CRISPR/Cas9 SYSTEM

Read more about ESTABLISHMENT OF PFIC 3 MOUSE MODEL CARRYING HUMAN-LIKE BILE ACID COMPOSITION BY IN VIVO LIVER-SPECIFIC GENE DELETION USING ADENO-ASSOCIATED VIRUS AND CRISPR/Cas9 SYSTEM

<div>Background: Progressive familial intrahepatic cholestasis (PFIC) 3 is a life-threatening hereditary disease caused by adenosine triphosphate-binding cassette subfamily B member 4 (ABCB4) gene mutations. The murine bile acid composition is different from that of humans. Mice are less likely to develop cholestasis due to the predominance of hydrophilic bile acids such as muricholic acids, which are synthesized by enzymes including Cyp2c70.

CHRONIC ETHANOL INSULT INCREASES HSD17beta13 ON HEPATOCELLULAR LIPID DROPLETS VIA A LOSS OF AN ASSOCIATED SEGREGASE p97/VCP TO PROMOTE HEPATIC STEATOSIS

Read more about CHRONIC ETHANOL INSULT INCREASES HSD17beta13 ON HEPATOCELLULAR LIPID DROPLETS VIA A LOSS OF AN ASSOCIATED SEGREGASE p97/VCP TO PROMOTE HEPATIC STEATOSIS

<div>Background: Chronic EtOH insult is known to lead to an accumulation of lipid droplets (LDs) in hepatocytes resulting in hepatic steatosis. Our previous study reported that EtOH resulted in a 10-fold reduction of the LD-associated segregase VCP/p97, a protein implicated in LD protein clearance. Concomitant with this decrease was a 6-fold increase in the association of the hydroxysteroid enzyme HSD17β13 known to play an important role in hepatic steatosis.

PSMP INHIBITS HCC PROGRESSION BY REGULATING THE POLARIZATION OF TUMOR-ASSOCIATED MACROPHAGES THROUGH THE PI3K/AKT PATHWAY

Read more about PSMP INHIBITS HCC PROGRESSION BY REGULATING THE POLARIZATION OF TUMOR-ASSOCIATED MACROPHAGES THROUGH THE PI3K/AKT PATHWAY

<div>Background: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and represents a major global health-care challenge. PC3 secreted microprotein (PSMP) is a novel chemotactic cytokine that can recruit peripheral blood monocytes and lymphocytes through its chemokine receptor CCR2. Our previous study found that PSMP is significantly highly expressed in human and mouse liver fibrosis/cirrhosis.

HEPATIC LOBULAR INFLAMMATION IS THE MOST IMPACTED PROGNOSTIC FACTOR RATHER THAN FIBROSIS IN PATIENTS WITH BIOPSY-PROVEN MASLD: MULTI-CENTER STUDY

Read more about HEPATIC LOBULAR INFLAMMATION IS THE MOST IMPACTED PROGNOSTIC FACTOR RATHER THAN FIBROSIS IN PATIENTS WITH BIOPSY-PROVEN MASLD: MULTI-CENTER STUDY

<div>Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) captures patients at high risk of hepatic fibrosis and cardiovascular disease. However, limited information is available on the prognosis of MASLD. This study aimed to investigate the prognosis of patients with biopsy-proven MASLD and validate a group of fatty liver patients excluded from MASLD because of no metabolic abnormalities by a multi-center longitudinal cohort.

HEAR-MHE: POINT-OF-CARE ANALYSIS OF RECORDED SPEECH AS A NOVEL METHOD TO DETECT HEPATIC ENCEPHALOPATHY

Read more about HEAR-MHE: POINT-OF-CARE ANALYSIS OF RECORDED SPEECH AS A NOVEL METHOD TO DETECT HEPATIC ENCEPHALOPATHY

<div>Background: Variation in speech may be an early sign of minimal hepatic encephalopathy (MHE) or future overt HE (OHE). Though a battery of tests is available for MHE assessment, these are cumbersome and rarely used in clinical practice. In a prospective study, we evaluated the ability of speech recorded at home or in the office to correlate with validated HE assessments in patients of diverse backgrounds.

AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE

Read more about AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE

<div>Background: This study extends the follow-up of participants who completed a randomized placebo-controlled trial evaluating the safety and efficacy of tenofovir disoproxil fumarate (TDF) in reducing the risk of histological progression in patients with chronic hepatitis B (CHB) characterized by high viral load and minimally raised serum alanine aminotransferase (ALT) levels. We report herein the outcomes of patients who received three years of open-label TDF treatment after completing a randomized trial

Subscribe to